Trevi Therapeutics, Inc. - Common Stock (TRVI)
CUSIP: 89532M101
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 128,120,714
- Total 13F shares
- 129,323,951
- Share change
- +14,684,100
- Total reported value
- $1,183,258,435
- Put/Call ratio
- 194%
- Price per share
- $9.15
- Number of holders
- 163
- Value change
- +$141,190,764
- Number of buys
- 99
- Number of sells
- 64
Quarterly Holders Quick Answers
What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89532M101:
Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. |
13D/G
|
— |
12%
|
15,074,080
|
$170,186,363 | $0 | 07 Aug 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
7%
|
8,508,021
|
$77,848,392 | -$16,025,200 | 30 Sep 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
10%
|
13,222,228
|
$72,325,588 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.6%
|
6,804,338
|
$62,259,693 | $0 | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
8%
|
10,259,409
|
$56,118,967 | — | 30 Jun 2025 | |
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
|
Company |
4.2%
|
5,128,875
|
$46,929,206 | -$21,747,894 | 30 Sep 2025 | |
| Rubric Capital Management LP |
13F
|
Company |
6.7%
|
8,531,860
|
$46,669,274 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
5,316,691
|
$29,082,300 | — | 30 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
3.5%
|
4,487,903
|
$24,548,829 | — | 30 Jun 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
3.3%
|
4,281,355
|
$23,419,012 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
3.2%
|
4,046,435
|
$22,133,999 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
3.1%
|
3,938,793
|
$21,545,198 | — | 30 Jun 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2.9%
|
3,672,000
|
$20,085,840 | — | 30 Jun 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
2.7%
|
3,406,955
|
$18,636,044 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2.6%
|
3,308,400
|
$18,096,948 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
2%
|
2,534,058
|
$13,861,297 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.9%
|
2,477,916
|
$13,554,200 | — | 30 Jun 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.8%
|
2,354,402
|
$12,878,579 | — | 30 Jun 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
1.7%
|
2,144,844
|
$11,732,296 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.4%
|
1,832,920
|
$10,026,072 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,786,845
|
$9,775,735 | — | 30 Jun 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.3%
|
1,728,676
|
$9,455,860 | — | 30 Jun 2025 | |
| Venrock Healthcare Capital Partners II, L.P. |
13D/G
|
— |
1.4%
|
1,266,457
|
$8,042,002 | $0 | 31 Dec 2024 | |
| TPG GP A, LLC |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
3,824,883
|
$7,726,264 | — | 01 Jul 2022 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
1,381,324
|
$7,555,842 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1%
|
1,319,266
|
$7,216,385 | — | 30 Jun 2025 | |
| Artia Global Partners LP |
13F
|
Company |
1%
|
1,311,840
|
$7,175,765 | — | 30 Jun 2025 | |
| Rosalind Advisors, Inc. |
13D/G
13F
|
Company |
1.2%
|
1,062,500
|
$6,746,875 | $0 | 13 Feb 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.89%
|
1,146,110
|
$6,269,222 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.86%
|
1,097,497
|
$6,003,308 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.84%
|
1,076,683
|
$5,889,456 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.8%
|
1,024,011
|
$5,601,339 | — | 30 Jun 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
0.76%
|
979,098
|
$5,355,666 | — | 30 Jun 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.66%
|
850,000
|
$4,649,500 | — | 30 Jun 2025 | |
| MAI Capital Management |
13F
|
Company |
0.66%
|
847,553
|
$4,636,115 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.64%
|
824,176
|
$4,508,000 | — | 30 Jun 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.62%
|
799,957
|
$4,375,765 | — | 30 Jun 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.55%
|
700,000
|
$3,829,000 | — | 30 Jun 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.51%
|
650,000
|
$3,555,500 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.45%
|
576,471
|
$3,153,297 | — | 30 Jun 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.44%
|
569,702
|
$3,116,270 | — | 30 Jun 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.42%
|
539,587
|
$2,951,541 | — | 30 Jun 2025 | |
| Burkehill Global Management, LP |
13F
|
Company |
0.41%
|
525,000
|
$2,871,750 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.4%
|
515,476
|
$2,819,653 | — | 30 Jun 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.39%
|
493,735
|
$2,700,730 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.38%
|
489,300
|
$2,676,471 | — | 30 Jun 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.38%
|
486,624
|
$2,661,833 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.35%
|
447,852
|
$2,449,750 | — | 30 Jun 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.3%
|
390,000
|
$2,133,300 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.29%
|
368,529
|
$2,015,855 | — | 30 Jun 2025 |
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock (TRVI) as of Q3 2025
As of 30 Sep 2025,
Trevi Therapeutics, Inc. - Common Stock (TRVI) was held by
163 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
129,323,951 shares.
The largest 10 holders included
NEA Management Company, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Rubric Capital Management LP, VANGUARD GROUP INC, VIKING GLOBAL INVESTORS LP, Vivo Capital, LLC, MARSHALL WACE, LLP, MORGAN STANLEY, and ALLIANCEBERNSTEIN L.P..
This page lists
163
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
153
Q3 2025 holders
163
Holder diff
10
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.